✦ LIBER ✦

An investigation of the familial aspects of carcinoma of the prostate

✍ Scribed by Charles M. Woolf

Publisher: John Wiley and Sons
Year: 1960
Tongue: English
Weight: 479 KB
Volume: 13
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(196007/08)13:4<739::aid-cncr2820130414>3.0.co;2-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Family history facilitates the early dia

Family history facilitates the early diagnosis of prostate carcinoma

✍ Patrick C. Walsh; Alan W. Partin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

## BACKGROUND. Although all men age ú50 years are at an increased risk for the development of prostate carcinoma, 2 major factors increase this risk: family history and race. This article outlines the influence of family history on the risk of prostate carcinoma and current understanding of factor

LV. Carcinoma of the prostate

📂 Article 📅 1934 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 1 views

## ARC'INORIA of the prostate most often begins between the agcs of 60 and 70, and has no recognized connection with senile enlargement or with prostatitis. Microscopically the growth is usually of scirrhous typc, but may also be an adenocarcsinoma with cubical or columnar cells. I n thc common s

An economic overview of prostate carcino

An economic overview of prostate carcinoma

✍ Hirsch S. Ruchlin; James M. Pellissier 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

Screening for carcinoma of the prostate

✍ Alexander, Freda E. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 25 KB 👁 2 views

Transitional cell carcinoma of the prost

Transitional cell carcinoma of the prostate

✍ Arnold B. Rubenstein; Myron E. Rubnitz 📂 Article 📅 1969 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB 👁 2 views

The biologic dilemma of early carcinoma

The biologic dilemma of early carcinoma of the prostate

✍ Andrew C. von Eschenbach 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 1 views

## BACKGROUND. The clinician has long been challenged by the diversity in clinical expression of carcinoma of the prostate. On one end of the spectrum is a disease that is phenotypically malignant but biologically not virulent. It is the prostate carcinoma that males die with rather than of. On th